Author(s):
Alexander Maniangat Luke, Sam Thomas Kuriadom, Mohammed Saleh Hamad Ingafou, Nireeksha
Email(s):
a.Luke@ajman.ac.ae
DOI:
10.52711/0974-360X.2026.00197 
Address:
Alexander Maniangat Luke1*, Sam Thomas Kuriadom1, Mohammed Saleh Hamad Ingafou1, Nireeksha2
1Department of Clinical Sciences, College of Dentistry, Ajman University, Ajman, UAE.
Center for Medical and Bio-Allied Health Sciences Research (CMBAHSR), Ajman University, Ajman, UAE.
2 Reader, Department of Conservative Dentistry and Endodontics, AB Shetty Memorial Institute of Dental Sciences, Nitte (Deemed to be) University, Deralakkatte ,Karnataka, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 3,
Year - 2026
ABSTRACT:
BACKGROUND AND AIM: This study explores the in vitro antitumor effects of clotrimazole, a well-established antifungal agent, on CAL-27 and UM 1 human OSCC cell lines. MATERIAL AND METHODS: Employing the MTT assay, we observed a dose-dependent reduction in cell viability following clotrimazole treatment, indicative of its potential cytotoxicity against OSCC cells. Results and conclusion: Flow cytometry analysis revealed a substantial increase in apoptotic cells, suggesting a pronounced pro-apoptotic effect. Concurrently, clotrimazole induced alterations in cell cycle progression, indicating a potential cytostatic impact on OSCC cells. Western blot analysis provided mechanistic insights, revealing changes in the expression of key regulatory proteins associated with apoptosis (e.g., caspases) and cell cycle control (e.g., cyclins and CDKs). Notably, clotrimazole exhibited a modulatory effect on signaling pathways implicated in cancer cell survival and proliferation, including the PI3K/Akt and MAPK pathways. These findings contribute to the growing body of evidence supporting clotrimazole's potential as an antitumor agent. The multifaceted impact of clotrimazole on OSCC cells, as demonstrated in this study, underscores its potential as a promising candidate for future OSCC therapeutic strategies.
Cite this article:
Alexander Maniangat Luke, Sam Thomas Kuriadom, Mohammed Saleh Hamad Ingafou, Nireeksha. In Vitro Assessment of Clotrimazole's anti-tumor effects on Oral Squamous Cell Carcinoma. Research Journal Pharmacy and Technology. 2026;19(3):1371-5. doi: 10.52711/0974-360X.2026.00197
Cite(Electronic):
Alexander Maniangat Luke, Sam Thomas Kuriadom, Mohammed Saleh Hamad Ingafou, Nireeksha. In Vitro Assessment of Clotrimazole's anti-tumor effects on Oral Squamous Cell Carcinoma. Research Journal Pharmacy and Technology. 2026;19(3):1371-5. doi: 10.52711/0974-360X.2026.00197 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-3-58
REFERENCES:
1. Pienaar ED. Young T. Holmes H. Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. Cochrane Database Syst Rev. 2010; (11).
2. Czerwinski R. Sivan S. Steinberg D. Gati I. Kagan L. A novel sustained-release clotrimazole varnish for local treatment of oral candidiasis. Clin Oral Investig. 2010; 14(1):71-8.
3. Penso J. Beitner R. Detachment of glycolytic enzymes from cytoskeleton of Lewis lung carcinoma and colon adenocarcinoma cells induced by clotrimazole and its correlation to cell viability and morphology. Mol Genet Metab. 2002; 76(3):181-8.
4. Gonçalves P. Gregório I. Araújo JR. Martel F. The effect of clotrimazole on energy substrate uptake and carcinogenesis in intestinal epithelial cells. Anticancer Drugs. 2012; 23(2):220-9.
5. Furtado CM. Marcondes MC. Sola-Penna M. de Souza ML. Zancan P. Clotrimazole preferentially inhibits human breast cancer cell proliferation, viability and glycolysis. PLoS One. 2012; 7(3):e30462.
6. Mhawech-Fauceglia P. Wang D. Kesterson J. Beck A. de Mesy Bentley KL et al. Aldolase mRNA expression in endometrial cancer and the role of clotrimazole in endometrial cancer cell viability and morphology. Histopathology. 2011; 59(5):1015-8.
7. Khalid MH. Tokunaga Y. Caputy AJ. Walters E. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg. 2005; 103(1):79-86.
8. Aktas H. Flückiger R. Acosta JA. Savage JM. Palakurthi SS et al. Depletion of intracellular Ca2+ stores, phosphorylation of eIF2 alpha, and sustained inhibition of translation initiation mediate the anticancer effects of clotrimazole. Proc Natl Acad Sci U S A. 1998; 95(14):8280-5.
9. Wang ZH. Shen B. Yao HL. Jia YC. Ren J. Blockage of intermediate-conductance Ca2+-activated K+ channels inhibits progression of human endometrial cancer. Oncogene. 2007; 26(35):5107-14.
10. Khalid MH. Shibata S. Hiura T. Effects of clotrimazole on the growth, morphological characteristics, and cisplatin sensitivity of human glioblastoma cells in vitro. J Neurosurg. 1999; 90(5):918-27.
11. Khalid MH. Tokunaga Y. Caputy AJ. Walters E. Inhibition of tumor growth and prolonged survival of rats with intracranial gliomas following administration of clotrimazole. J Neurosurg. 2005; 103(1):79-86.
12. Ito C. Tecchio C. Coustan-Smith E. Suzuki T. Behm FG. The antifungal antibiotic clotrimazole alters calcium homeostasis of leukemic lymphoblasts and induces apoptosis. Leukemia. 2002; 16(7):1344-52.
13. Zhang L. Liao QP. Wang CH. Zhang D. Zheng JH. Wang Y et al. Trends in targeting Bcl-2 anti-apoptotic proteins for cancer treatment. Eur J Med Chem. 2020; 232:114184.
14. Liu H. Li Y. Raisch KP. Clotrimazole induces a late G1 cell cycle arrest and sensitizes glioblastoma cells to radiation in vitro. Anticancer Drugs. 2010; 21(9):841-9.
15. Coelho RG. Calaça IC. Celestrini DM. Correia AH. Costa MA. Clotrimazole disrupts glycolysis in human breast cancer without affecting non-tumoral tissues. Mol Genet Metab. 2011; 103(4):394-8.
16. Marcondes MC. Sola-Penna M. Zancan P. Clotrimazole potentiates the inhibitory effects of ATP on the key glycolytic enzyme 6-phosphofructo-1-kinase. Arch Biochem Biophys. 2010; 497(1-2):62-7.
17. Katanyoo K. Sanguanrungsirikul S. Manusirivithaya S. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma in locally advanced cervical cancer. Gynecol Oncol. 2012; 125(2):292-6